Severe fungal lung infections create a paradox: the immune system becomes paralyzed precisely when it needs to fight hardest. This immune shutdown phenomenon, long observed in critically ill patients, may now have a potential therapeutic solution through cancer immunotherapy drugs repurposed for infectious disease. Mouse studies reveal that invasive mucormycosis - a deadly mold infection with mortality rates exceeding 50% in humans - triggers rapid immune exhaustion within seven days. The lungs show suppressed inflammatory responses, weakened T-cell signaling, and upregulation of checkpoint proteins that normally prevent autoimmunity but inadvertently disable infection-fighting capabilities. Anti-PD-L1 antibodies, already FDA-approved for certain cancers, successfully reversed this immune paralysis when combined with standard antifungal treatment. Early intervention proved superior to delayed therapy, significantly improving survival rates and restoring proper immune cell activation. The treatment reactivated cytokine pathways and reinvigorated helper T-cells that coordinate the body's defense against pathogens. This research addresses a critical gap in treating invasive fungal infections, which disproportionately affect immunocompromised patients including those with cancer, organ transplants, or severe COVID-19. While mucormycosis affects relatively few people, similar immune paralysis patterns appeared across different fungal species, suggesting broad therapeutic potential. The findings challenge the conventional approach of relying solely on antifungal drugs, particularly given rising antifungal resistance. However, translating these mouse results to human patients requires careful consideration of dosing, timing, and potential autoimmune complications from checkpoint inhibition in already vulnerable populations.